CASE REPORT

Manifestation of glucose-6-phosphate dehydrogenase deficiency in the wake of new-onset type 1 diabetes mellitus: a case report

Sandhya Govindarajan1*, Imran Zamir2, Sunil Bagewadi3 and Emily Moore4

Abstract

Background: Diabetes mellitus is the most common metabolic disease globally, while glucose-6-phosphate dehydrogenase deficiency, an X-linked inherited disorder, is the most common erythrocyte enzyme defect. The association between the two in children has been infrequently reported.

Case presentation: We report the case of a 10-year-old boy of Iraqi descent who presented to our emergency department with new-onset type 1 diabetes mellitus without Diabetic Keto Acidosis. He was treated with subcutaneous insulin and discharged. Eleven days after hospitalization, he was found to be jaundiced during his home visit. Hence, he was referred to the pediatric unit, and his hemoglobin had declined from 130 g/L at the previous admission to 81 g/L. Blood tests revealed low haptoglobin, and his peripheral blood film showed anisocytosis, polychromasia, and occasional red cell fragments suggestive of acute hemolysis. His glucose-6-phosphate dehydrogenase activity was very low, and his subsequent genetic tests confirmed Mediterranean-type glucose-6-phosphate dehydrogenase deficiency.

Conclusion: Glucose-6-phosphate dehydrogenase deficiency in people with diabetes mellitus has been underreported in the literature so far, and screening of glucose-6-phosphate dehydrogenase deficiency should be considered on diagnosis of diabetes mellitus, especially in boys of African, Mediterranean, or Asian descent.

Keywords: Diabetes mellitus, G6PD deficiency

Background

Type 1 diabetes mellitus, a common metabolic disorder, has a global prevalence of 5.9 per 10,000, with a prevalence of 9.6 per 10,000 in Asia and 5.3 per 10,000 in Africa [1]. The association between diabetes mellitus and hemolysis due to G6PD deficiency has been reported previously, but the underlying mechanisms are not yet fully understood. Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that makes up part of the pentose phosphate pathway. It maintains adequate levels of nicotinamide dinucleotide phosphate (NADPH) in red blood cells. NADPH plays a role in ensuring there is adequate glutathione to allow the cell to withstand oxidative damage and therefore prevent hemolysis. A reduction or deficiency of G6PD enzyme activity leads to an increased risk of hemolysis, particularly in the presence of oxidative stress. The condition has X-linked inheritance. Heterozygous females are usually unaffected, and there are varying degrees of severity depending on the levels of enzyme activity [2]. Worldwide, 400 million people are affected,
most commonly from Africa, Middle East, Asia, Papua New Guinea, and the Mediterranean [2]. Most people with this condition are asymptomatic until hemolysis is induced by known triggers such as fava bean ingestion (broad beans), certain drugs, sepsis, renal failure, and Diabetic Keto Acidosis (DKA) [2].

**Case presentation**

We describe the case of a 10-year-old Iraqi descent boy who presented to our emergency department with a history of lethargy, weight loss, polydipsia, and polyuria for 2 weeks. He was born in the UK to parents of Iraqi origin. His past medical history included nocturnal enuresis and an adenotonsillectomy. He is one of five children, and there is no family history of any medical condition. He was not on any regular medications. His weight at presentation was 56.6 kg. His initial laboratory blood glucose was found to be raised (42.9 mmol/l), and venous blood gas revealed a pH of 7.380 (7.35–7.45), bicarbonate 21.3 (21–28) mmol/L, and base deficit of 3.3 (2 to +3) mmol/L. His urine ketones were found to be negative. He was diagnosed with new-onset type 1 diabetes mellitus (DM) presenting without DKA. His blood results showed hemoglobin of 130 (111–147) g/L, white blood cell count of 8.1 × 10⁹/L, and platelet count of 274 × 10⁹/L, and base deficit of 3.3 (2 to +3) mmol/L. His urine ketones were found to be negative. He was referred to the acute pediatric observation unit. On examination, there was no malaise. He was admitted to hospital, where he underwent a baseline investigation with regard to cause of his anemia. He was investigated for causes of hemolytic anemia and jaundice such as hereditary spherocytosis, thalassemia, autoimmune hemolytic anemia, viral hepatitis, and G6PD deficiency. His serum iron levels, transferrin levels, and coagulation profile were within normal limits, and his hemoglobinopathy screen showed no evidence of thalassemia or abnormal hemoglobin. Direct agglutinin test was negative. His G6PD assay by spectrophotometry showed significantly low activity, that is, < 0.4 (4.8–13.6) IU/gHb. Virology testing showed a negative test for human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C. There was evidence of past infection with Epstein–Barr virus (EBV), cytomegalovirus (CMV), and parvovirus but not of acute infection. Diagnosis of G6PD deficiency was confirmed following the enzyme assay result, which was available 2 days later. The patient remained in hospital until this diagnosis was made and remained clinically stable. His genetic results later confirmed hemizygous G6PD c.653C>T; p. (ser218phe) pathogenic variant, consistent with the diagnosis of Mediterranean-type G6PD deficiency.

**Further investigations**

The combination of the sudden drop in hemoglobin from 130–81 g/L within 11 days with jaundice prompted further investigation with regard to cause of his anemia. His blood film revealed anisocytosis, spherocytes, polychromasia, and occasional red cell fragments suggestive of acute hemolysis. Further blood workup showed lactate dehydrogenase levels of 243 (125–243) units/L and low haptoglobin levels of < 0.08 (0.50–2.00) g/L.

**Differential diagnosis**

He was investigated for causes of hemolytic anemia and jaundice such as hereditary spherocytosis, thalassemia, autoimmune hemolytic anemia, viral hepatitis, and G6PD deficiency. His serum iron levels, transferrin levels, and coagulation profile were within normal limits, and his hemoglobinopathy screen showed no evidence of thalassemia or abnormal hemoglobin. Direct agglutinin test was negative. His G6PD assay by spectrophotometry showed significantly low activity, that is, < 0.4 (4.8–13.6) IU/gHb. Virology testing showed a negative test for human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C. There was evidence of past infection with Epstein–Barr virus (EBV), cytomegalovirus (CMV), and parvovirus but not of acute infection. Diagnosis of G6PD deficiency was confirmed following the enzyme assay result, which was available 2 days later. The patient remained in hospital until this diagnosis was made and remained clinically stable. His genetic results later confirmed hemizygous G6PD c.653C>T; p. (ser218phe) pathogenic variant, consistent with the diagnosis of Mediterranean-type G6PD deficiency.

**Treatment**

He did not undergo blood transfusion but was commenced on folic acid in view of his active hemolysis by the hematology team. The rationale behind prophylactic administration of folic acid is that acute hemolysis can consume folate and lead to megaloblastic anemia [3]. During his stay, repeat full blood counts were performed that showed a rising trend in hemoglobin. Four days following admission, hemoglobin had risen to 89 g/L and reticulocytes were at 22.8%. He was discharged on folic acid 5 mg once a day for 12 weeks with planned follow-up with diabetes team and hematology team.
Outcome and follow-up
Blood testing 1 month later showed complete recovery of hemoglobin levels (136 g/L) and liver function tests (serum bilirubin 12 μmol/L).

He was kept under follow-up for diabetes mellitus and G6PD deficiency. Assessment of HbA1C levels repeated after 2 months revealed 45 (20–41) mmol/mol. He is currently on long-acting basal insulin (Degludec) and insulin aspart (Fiasp) for his diabetes and is under follow-up with the diabetic team and hematology team. He successively developed three further episodes of mild jaundice following hemolysis during acute illnesses, including one episode of cellulitis and two episodes of respiratory tract infection, in a period of 1 year, suggesting that G6PD Mediterranean type presents with enzyme deficiencies that are more severe than in the other G6PD variants.

Discussion
G6PD is involved in the pentose phosphate pathway, which catalyzes the reaction that produces NADPH, by which erythrocytes protect themselves from hemolysis caused by oxidative stress [4]. It also replenishes the reduced form of glutathione, which maintains hemoglobin in reduced form [4]. Hemolysis in patients with G6PD deficiency during treatment of type 1 diabetes mellitus has been reported previously; however, the mechanism behind it is not yet fully understood [5,6].

To date, 25 cases have been reported from 12 different countries in both type 1 and type 2 diabetes mellitus in patients aged 4 years [6] to 58 years [7]. Hypoglycemia [8], blood glucose normalization [9], ketoacidosis [5], and administration of metformin [10] or glibenclamide [7] are considered as possible causes of hemolysis in patients with DM and underlying G6PD deficiency. Blood glucose normalization after treatment with insulin could have been a likely cause of hemolysis in our patient. During administration of insulin, the drop in blood glucose levels causes NADPH loss in red blood cells, which makes them sensitive to oxidative stress [11,12]. This, combined with loss of sulfhydryl group availability due to G6PD deficiency, is likely to trigger hemolytic anemia in patients with type 1 diabetes mellitus [12].

Gradual plasma glucose correction to avoid rapid decrease in glucose availability for red blood cells is likely to reduce the occurrence of hemolysis in G6PD-deficient patients [13]. Also, screening of G6PD enzyme activity should be considered in patients newly diagnosed with diabetes, especially in boys, considering the ethnic origin of the patient, to reduce the risk of hemolysis. G6PD deficiency screening is a cost-effective test at a rate of about 3 USD per screening test and is considered economical compared with the average cost of hospitalization due to hemolysis secondary to G6PD deficiency [14].

Glycosylated hemoglobin (HbA1c) is an important determinant of diabetes control and reflects the mean glycemic level over the preceding 120 days, which is the average lifespan of a red blood cell. The HbA1c level at any point in time is contributed to by all the circulating erythrocytes, from the oldest (120 days old) to the youngest [15]. False low HbA1c has been reported in glucose-6-phosphate dehydrogenase deficiency due to increased red cell turn over [15] and reduced exposure time of hemoglobin to glucose [16]. Hence, HbA1C levels may not be a reliable indicator of adequate glycemic control in a patient with type 1 diabetes mellitus with underlying G6PD deficiency.

Conclusion
1. We hypothesize that, on the basis of the global prevalence of both conditions, G6PD deficiency in people with diabetes mellitus has been underreported in the literature so far, and screening of G6PD deficiency, being a cost-effective test, should be considered on diagnosis of diabetes mellitus, especially in boys of African, Mediterranean, or Asian descent.
2. HbA1C levels might not be always reliable for monitoring glycemic control in a diabetic patient with G6PD deficiency.
3. Hemolysis may occur during normalization of blood glucose levels in a G6PD-deficient patient with diabetes such as after treatment of DKA.

Acknowledgements
We acknowledge the patient and the parents of the patient, as well as the Department of Hematology and Department of Genetics, Royal Manchester Children's Hospital.

Author contributions
SG—contributed to drafting case report, including discussion. IZ and SB—consultants involved in patient care and in editing the manuscript, including seeking parent/guardian’s consent. EM—contributed to database search. All authors read and approved the final manuscript.

Funding
Not applicable. This case report received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author (SG) upon reasonable request.

Declarations
Ethics approval and consent to participate:
Not applicable. No ethical approval involved as it a case report. Written consent taken from patient’s guardian for participating in this case report.

Conflict of interest
The authors declare no conflicts of interest.
Consent for publication
Written informed consent was obtained from the patient’s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author details
1. Department of Paediatrics, North Manchester General Hospital, Manchester, England. 2. North Manchester General Hospital, Manchester Foundation Trust, Manchester, England. 3. Northern Care Alliance, Manchester, England. 4. Paediatrics and Neonates Trainee, North Manchester General Hospital, Manchester, England.

Received: 16 June 2021   Accepted: 29 July 2022
Published online: 26 August 2022

References
1. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98–115. https://doi.org/10.34172/hpp.2020.18.
2. BMJ Best Practice G6PD deficiency [Internet]. 2022. [https://patient.info/doctor/glucose-6-phosphate-dehydrogenase-deficiency]. Accessed 3 July 2022.
3. Chanarin I, Dacie JV, Mollin DL. Folic-acid deficiency in haemolytic anaemia. Br J Haematol. 1959;5:245–56. https://doi.org/10.1111/j.1365-2141.1959.tb04032.x.
4. Silvestri F, Ortuso S, Dicanio D, Costantino F. Glucose-6-phosphate dehydrogenase deficiency unmasked by hyperglycemia. Pediatr Ther. 2015;5:1–2.
5. “Young type 1 diabetes mellitus (T1DM) patient with glucose-6-phosphate dehydrogenase deficiency occurring hemolysis: A case report.” Biomedical Research [Internet]. 2022. [https://www.alliedacademies.org/articles/young-type-1-diabetes-mellitus-t1dm-patient-with-glucose6phosphate-dehydrogenase-deficiency-occurring-hemolysis-a-case-report-8202.html]. Accessed 3 July 2022.
6. Orman B, Çetinkaya S, Öner N, Akçaboy M, Fettah A, GülerayLafcı N, Savaş EŞ. Hemolytic anemia due to glucose 6-phosphate dehydrogenase deficiency triggered by type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2022. [https://doi.org/10.4274/jcrpe.galenos.2021.2021-11-10].
7. Vinzio S, André E, Perrin AE, Schlienger J, Goichot B. Gilbert’s syndrome in acute haemolytic anaemia revealing a G6PD deficiency. Diabetes Res Clin Pract. 2004;64(3):181–3. https://doi.org/10.1016/j.diabres.2003.11.006.
8. Shalve O, Elakim R, Lugassy GZ, Menzel J. Hypoglycemia-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency. Acta Haematol. 1985;74(4):227–9. https://doi.org/10.1111/j.1365-2141.1985.tb04032.x.
9. Vanelli M, Lucentini L, Picco P, Galanello R, Chian G, Adinolfi B, Street ME. Blood glucose normalisation-induced haemolysis in three adolescents with type 1 diabetes mellitus at onset and unknown G-6-PD deficiency. J Pediatr Endocrinol Metab. 1996;9(2):193–6.
10. Meir A, Kleinman Y, Rund D, Da’as N. Metformin-induced hemolytic anemia in a patient with glucose-6-phosphate dehydrogenase deficiency. Diabetes Care. 2003;26(3):956–7.
11. Messina MF, Lombardo F, Crisafulli G, Salzano G, Rosano M, Di Giorgio RM. Hemolytic crisis in a non-ketoic and euglycemic child with glucose-6-phosphate dehydrogenase deficiency and onset of type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2004;17(12):1671–3. https://doi.org/10.1515/jpem.2004.17.12.1671.
12. Enrico MK, Kovace B, Bernardini A, et al. Haemolysis during diabetic ketoacidosis treatment in two girls with incomplete glucose-6-phosphate dehydrogenase deficiency. Acta Biomed. 2009;80(1):69–72.
13. Aljishi F, ALDarwish M. Glucose-6-phosphate dehydrogenase deficiency induced haemolysis in a woman with newly diagnosed diabetes after normalisation of hyperglycaemia. Diabet Med. 2017;34(9):1318–1321. https://doi.org/10.1111/dme.13385.
14. Khnissi J, Adib SM, Loiselet J, Mejargbane A. Cost–benefit analysis of G6PD screening in Lebanese newborn males. J Med Liban. 2007;55(3):129–32.
15. Aggarwal N, Rai AK, Kupfer Y, Tessler S. Immeasurable glycosylated haemoglobin: a marker for severe haemolysis. BMJ Case Rep. 2013. [https://doi.org/10.1136/bcr-2013-200307].
16. Danzig JA, Moser JT, Belfield P, et al. Glucose-6-phosphate dehydrogenase deficiency diagnosed in an adolescent with type 1 diabetes mellitus and HbA1c discordant with blood glucose measurements. J Padiatr. 2011;2013:849–51.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions